All In Biotech

NDA 021077 · Glaxo Grp LTD

Advair Diskus 500/50

Fluticasone Propionate, Salmeterol Xinafoate · Inhalation

Last checked: Nov 20, 2026Latest source record: Jan 7, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Aug 24, 2000

Approved uses

7

Original approval plus efficacy supplements

Registered trials

738

240 Phase 3, 19 recruiting

FAERS reports

37,187

15,488 serious, 1,918 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 6, 2026.

Fluticasone Propionate/Salmeterol DISKUS is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist (LABA) indicated for: • Twice-daily treatment of asthma in patients aged 4 years and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). ( 1.2 ) Important limitation of use: Not indicated for relief of acute bronchospasm. ( 1.1 , 1.2 ) 1.1 Treatment of Asthma Fluticasone Propionate/Salmeterol DISKUS is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. Fluticasone Propionate/Salmeterol DISKUS should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta 2 -adrenergic agonist (LABA). Important Limitation of Use Fluticasone Propionate/Salmeterol DISKUS is NOT indicated for the relief of acute bronchospasm. 1.2 Maintenance Treatment of Chronic Obstructive Pulmonary Disease Fluticasone Propionate/Salmeterol DISKUS inhalation powder 250/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Fluticasone Propionate/Salmeterol DISKUS inhalation powder 250/50 mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. Fluticasone Propionate/Salmeterol DISKUS inhalation powder 250/50 mcg twice daily is the only approved dosage for the treatment of COPD because an efficacy advantage of the higher strength Fluticasone Propionate/Salmeterol DISKUS inhalation powder 500/50 mcg...

Mechanism: Fluticasone Propionate/Salmeterol DISKUS Fluticasone Propionate/Salmeterol DISKUS contains both fluticasone propionate and salmeterol. The mechanisms of action described below for the individual components apply to Fluticasone Propionate/Salmeterol DISKUS. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices. Fluticasone Propionate Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ADVAIR DISKUS 500/50 · FLUTICASONE PROPIONATE 0.5MG/INH; SALMETEROL XINAFOATE EQ 0.05MG BASE/INH · POWDER, INHALATION · Prescription · TE AB
  • ADVAIR DISKUS 100/50 · FLUTICASONE PROPIONATE 0.1MG/INH; SALMETEROL XINAFOATE EQ 0.05MG BASE/INH · POWDER, INHALATION · Prescription · TE AB
  • ADVAIR DISKUS 250/50 · FLUTICASONE PROPIONATE 0.25MG/INH; SALMETEROL XINAFOATE EQ 0.05MG BASE/INH · POWDER, INHALATION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluticasone Propionate" as an intervention, any sponsor and status, largest first.

All 738 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea5,839
  • drug ineffective4,379
  • product quality issue2,508
  • cough2,235
  • product dose omission issue2,116
  • pneumonia2,059
  • drug dose omission1,996
  • asthma1,915
  • malaise1,509
  • wrong technique in device usage process1,483
  • device use error1,445
  • chronic obstructive pulmonary disease1,308

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004163
200579
200613
200715
200816
200934
2010328
2011624
20121,675
20134,671
20143,787
20155,405
20163,618
20173,249
20183,280
20192,604
20201,753
20211,204
20221,130
2023936
20241,089
2025586
2026925

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,187 on PubMed

Sponsor: GSK · Also marketed as Advair Diskus 100/50, Advair Diskus 250/50

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.